Research
Diosmin
48 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Role of veno-active drugs after endovenous therapy: A systematic review of the current literature.
Systematic review of seven studies (four RCTs and three cohort studies) involving 1703 participants, assessing the effects of venotonic drugs like MPFF and diosmin + Centella asiatica + vitamin C after endovenous therapy. MPFF showed significant benefits in pain reduction in 75% of assessments. No detrimental effects were reported.
Efficacy of Diosmin in Reducing Lower-Extremity Swelling and Pain After Total Knee Arthroplasty: A Randomized, Controlled Multicenter Trial.
Randomized controlled multicenter trial of 330 patients undergoing total knee arthroplasty, comparing diosmin to no treatment. Diosmin reduced lower-extremity swelling and pain during motion but showed no significant differences in pain at rest, functional scores, range of motion, inflammatory biomarkers, or complication rates.
Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease.
Systematic review and expert meeting report on the impact of chronic venous disease (CVD) on health-related quality of life (HRQoL) and the effectiveness of veno-active drugs (VADs) like MPFF, aminaphthone, and diosmin. MPFF showed significant improvements in HRQoL in both RCTs and observational studies, while other VADs had limited evidence.
[Common sense of diosmin administration in combined treatment of hemorrhoids].
Meta-analysis and Cochrane review of flavonoids, including diosmin, in the treatment of hemorrhoids. The analysis included 24 randomized controlled trials with 2,334 participants, comparing flavonoids to placebo. Flavonoids are recommended as part of complex therapy for hemorrhoids, though no conclusive evidence favors one specific flavonoid or dosage.
Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema.
Meta-analysis of 10 RCTs with 1010 patients comparing venoactive drugs to placebo for reducing venous ankle edema. MPFF showed the greatest reduction in ankle circumference, significantly superior to placebo and other venoactive agents.
Micronized diosmin (Detralex) for vein-related trophic ulcers: European experience.
Meta-analysis of 5 large European studies involving 723 patients with venous trophic ulcers treated with micronized diosmin. The analysis showed a statistically significant clinical effect on middle-sized trophic ulcers that persisted for 6-12 months, supporting the use of micronized diosmin as part of complex therapy for chronic venous insufficiency.
Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
The RELIEF study was a multicentric, international RCT involving 5,052 patients with chronic venous insufficiency (CVI) treated with micronized purified flavonoid fraction (MPFF) over 6 months. The study assessed symptom severity and quality of life improvements, finding significant symptom reduction and quality of life enhancement in patients, particularly those without venous reflux.
Venoactive drug treatment for patients with pelvic varicose veins: Results of the single-center, randomized, open-label study (VENOTREAT).
This randomized, open-label study evaluated the efficacy and safety of diosmin-containing agents in 150 women with pelvic venous disorder. The study found that micronized purified flavonoid fraction (MPFF) provided faster and greater reduction in chronic pelvic pain compared to diosmin and hesperidin-diosmin combination, with pain elimination by day 28 in the MPFF group. Adverse events were mild and included headache, nausea, gastralgia, and diarrhea.
Swelling Management in Total Knee Arthroplasty: A Systematic Review.
Systematic review of 140 clinical studies on interventions to reduce postoperative swelling after total knee arthroplasty. Tranexamic acid, tourniquet minimization, knee flexion, and cryotherapy were most effective. Diosmin, acupuncture, and kinesiotaping were mentioned as adjunctive therapies.
Efficacy of a Low-Dose Diosmin Therapy on Improving Symptoms and Quality of Life in Patients with Chronic Venous Disease: Randomized, Double-Blind, Placebo-Controlled Trial.
This randomized, double-blind, placebo-controlled trial evaluated the efficacy of low-dose diosmin (μsminPlus) in improving symptoms and quality of life in patients with Chronic Venous Disease (CVD). The study found significant improvements in leg edema, VAS score, GIS, and VCSS scores in the diosmin group compared to placebo, with no treatment-related side effects.
Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study.
This RCT assessed the efficacy and safety of adding diosmin 600 mg to rivaroxaban and elastic compression stockings in patients with femoropopliteal DVT. The experimental group showed significantly lower post-thrombotic syndrome frequency, quicker vein recanalization, and improved clinical scores compared to the control group after 12 months.
Surgical correction of varicose vein disease under micronized diosmin protection (results of the Russian multicenter controlled trial DEFANS).
The DEFANS trial evaluated the efficacy and safety of micronized diosmin (Detralex) in 245 patients undergoing phlebectomy for varicose vein disease. The main group received diosmin pre- and post-surgery, showing reduced pain, subcutaneous hemorrhage, and improved exercise tolerance compared to controls.
Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.
RCT comparing the effects of oxerutins (Venoruton) and micronized diosmin + hesperidin (Daflon) on venous-related quality of life (Ve-QOL) in patients with chronic venous insufficiency. The oxerutins group showed a significant improvement in Ve-QOL score (46.8%) compared to the D+H group (15.5%). Oxerutins were found to be more effective in improving CVI symptoms and quality of life.
Effects of the Flavonoid Diosmin on Post Exercise Muscle Soreness - A Randomized Controlled Trial.
A randomized, double-blind, placebo-controlled crossover trial evaluated the effects of diosmin supplementation on athletic performance and DOMS-related symptoms in 15 professional female futsal athletes. Diosmin showed trivial-to-moderate effects on reducing oxidative damage, muscle soreness, and improving muscle strength and postural balance, though these effects were not statistically significant.
Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study.
RCT evaluating the efficacy of a flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in reducing bleeding from I-III degree hemorrhoidal disease. The study involved 154 patients, with improvements in bleeding observed in both the study and control groups. Satisfaction was significantly higher in the study group.
Effectiveness and safety of a product containing diosmin, coumarin, and arbutin (Linfadren®) in addition to complex decongestive therapy on management of breast cancer-related lymphedema.
RCT assessing the effectiveness and safety of Linfadren (containing diosmin, coumarin, and arbutin) in addition to complex decongestive therapy (CDT) for breast cancer-related lymphedema. Linfadren addition resulted in greater reduction of excess volume and improved QuickDASH scores compared to CDT alone, with no adverse events reported.
A Randomized Controlled Trial Evaluating the Effects of Diosmin in the Treatment of Radicular Pain.
RCT evaluating the effects of Diosmin in treating radicular pain in 150 patients. Diosmin was administered orally at 50 mg/kg/day for one month. The study found that Diosmin reduced radicular pain with a total satisfaction rate of 84.7% and no adverse effects reported.
Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial.
Prospective, randomized, triple-blind, controlled trial of 134 patients with acute hemorrhoidal crisis comparing a mixture of diosmin, troxerutin, and hesperidin to placebo. The treatment group showed significant reductions in pain, bleeding, edema, and thrombosis after 12 days, with reduced use of painkillers.
Effects of a new nutraceutical substance on clinical and molecular parameters in patients with chronic venous ulceration.
RCT evaluating the effects of Axaven, a new nutraceutical, on clinical and molecular parameters in 83 patients with chronic venous ulceration. Axaven decreased inflammatory cytokines, MMPs, and NGAL, improving symptoms and increasing wound healing speed.
A randomized, controlled clinical pilot study comparing three types of compression therapy to treat venous leg ulcers in patients with superficial and/or segmental deep venous reflux .
A randomized clinical pilot study among 70 patients with venous leg ulcers compared three types of compression therapy: intermittent pneumatic compression, stockings, and short-stretch bandages. All patients received saline-soaked gauze dressings along with micronized purified flavonoid fraction, diosmin, hesperidin, and Daflon 500. Wound size reduction and healing rates were significantly higher in groups receiving intermittent pneumatic compression or stockings compared to short-stretch bandages.
How we can improve patients' comfort after Milligan-Morgan open haemorrhoidectomy.
An observer-blinded, randomized trial with 86 patients compared post-haemorhoidectomic symptoms using Diosmin flavonidic fraction versus placebo. Diosmin significantly improved pain, heaviness, bleeding, pruritus, and reduced hospitalization time after surgery. No statistical difference was found in wound mucosal discharge between groups.
[Results of a multicentre clinical trial studying efficacy and safety of Vasocet in patients with varicose disease and chronic venous insufficiency].
Multicenter prospective clinical trial assessing quality of life in patients with chronic venous insufficiency using nonmicronized diosmin (Vasocet). Specialized questionnaires (CIVIQ-2) were used to evaluate changes in quality of life.
Medicamentous treatment of chronic venous insufficiency using semisynthetic diosmin--a prospective study.
Prospective study of semisynthetic diosmin on 80 patients with chronic venous insufficiency (HVI). Treatment with Phlebodia 600 for 30 days resulted in significant improvement in clinical signs, quality of life, and CEAP stage of HVI.
HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial.
RCT comparing Venoruton (HR) and Daflon in 90 patients with chronic venous insufficiency. Venoruton significantly improved microcirculatory parameters and symptoms, while Daflon showed no significant changes. No side effects or drop-outs were observed.
[Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"].
Double-blind, placebo-controlled therapeutic trial comparing the efficacy of two formulations of diosmin (600 mg once daily vs 300 mg twice daily) in non-menopaused women with heavy legs syndrome. The study found similar efficacy between the two regimens, with a small but significantly better improvement in patient self-evaluation for the 600 mg formulation, particularly in the first two weeks.
Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy.
A prospective randomized controlled trial on the effects of Daflon 500 mg (containing diosmin and hesperidin) on bleeding after haemorrhoidectomy in 228 patients. Postoperative bleeding was significantly reduced in the group receiving Daflon compared to controls, with no side-effects reported.
Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis.
RCT assessing the effect of diosmin administration (2 x 600 mg daily) on angiogenesis-related factors in 35 patients with chronic venous disorders (CVD). Significant decreases in TNF alpha, VEGF-C, VEGF-A, IL-6, and FGF2 levels, and a significant increase in angiostatin were observed. Clinical symptoms of CVD, including edema and leg circumference, improved after three months of diosmin therapy.
Comparative Bioavailability of Two Diosmin Formulations after Oral Administration to Healthy Volunteers.
Cross-over clinical study comparing the pharmacokinetic profile of µSminPlus, a micronized diosmin flavonoid complex, to unformulated micronized diosmin in 16 healthy volunteers. The tested formulation showed higher plasmatic concentrations of diosmetin and greater relative bioavailability than the reference.
Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects.
An open-label, sequential, two-period study in 12 healthy male volunteers assessed the influence of diosmin on the metabolism and pharmacokinetics of carbamazepine. Diosmin treatment significantly altered the pharmacokinetics of carbamazepine, suggesting a pharmacokinetic interaction due to CYP3A4 enzyme inhibition.
[Clinical observation of auricular point sticking combined with western medicine for preventing and treating postoperative complications of external excision and internal ligation on mixed hemorrhoid].
RCT of 80 patients with mixed hemorrhoid comparing auricular point sticking combined with conventional western medicine (paracetamol, dihydrocodeine tartrate, and diosmin) to conventional treatment alone. The observation group showed lower scores of pain, edema, hematochezia, and retention of urine on the 1st and 2nd days post-operation compared to the control group.
Micronized purified flavonoid fraction in pretreating CABG patients.
This prospective, randomized trial studied the effects of oral pretreatment with micronized purified flavonoid fraction (Daflon) on cardiac function and outcomes in 43 patients undergoing coronary artery bypass grafting. The Daflon group showed significantly lower troponin I and lactate dehydrogenase levels postoperatively, and improved New York Heart Association status, suggesting potential benefits for heart health.
[Semisynthetic Diosmin (Phlebodia 600) for therapy of lower limb chronic venous insufficiency].
RCT assessing the clinical effectiveness of semisynthetic Diosmin (Phlebodia 600) in patients with chronic venous insufficiency (CVI). Phlebodia 600 demonstrated a positive effect on CVI symptoms, edematous and convulsive syndromes, and was concluded to be highly effective and safe.
Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers.
This study evaluated the pharmacokinetic parameters of Venoruton, focusing on the bioavailability of its derivatives mono-3'-HQ and mono-4'-HQ in 16 healthy volunteers. The study found that the bioavailability of both derivatives tended to be proportional to the dose, and the different doses were safe and well tolerated.
Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting.
This study investigated the influence of particle size on the absorption of diosmin after oral administration of micronized and nonmicronized diosmin in 12 healthy male volunteers. The absorption of micronized diosmin was significantly improved compared to nonmicronized diosmin, as measured by urinary excretion of total radioactivity.
Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.
A double-blind, randomized controlled trial evaluated the efficacy of Daflon 500 mg (diosmin) in venous ulcer healing. The study involved 107 patients, with a two-month treatment of diosmin or placebo in addition to compression therapy. Results showed a significantly higher rate of complete ulcer healing in the diosmin group for ulcers ≤ 10 cm, with no significant differences in secondary criteria except for sensation of heavy legs and ulcer appearance.
Controlled studies of Daflon 500 mg in chronic venous insufficiency.
Three double-blind, randomized trials investigated the efficacy of Daflon 500 mg, a micronized flavonoid mixture of 90% diosmin and 10% hesperidin, in patients with chronic venous insufficiency. Daflon 500 mg significantly decreased venous capacitance, venous distensibility, and venous emptying time, with improvements in clinical symptoms and a decrease in supramalleolar circumference.
A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.
A double-blind, randomized, placebo-controlled trial studied the efficacy and safety of a veno-active flavonoid fraction (S 5682) consisting of micronized diosmin and hesperidin in 100 patients with symptomatic capillary fragility. The S 5682 group showed significantly higher capillary resistance and improvement in symptoms compared to placebo, with no significant side-effects.
Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids.
A double-blind, controlled study on the effectiveness of oral diosmin (Daflon) in treating acute symptoms of first-degree and second-degree internal hemorrhoids in 100 patients. The diosmin group showed statistically significant objective improvement on the fourth day, but no significant difference in subjective or objective improvement at day 14 compared to placebo.
[Randomized study of the use of synthetic diosmin in premenstrual and vascular dysplastic mastodynia].
RCT studying the antalgic effect of synthetic diosmin in 120 patients with vascular and premenstrual mastodynia compared to controls. The treated group showed a significant decrease in painful symptomatology, which was maintained over one year.
Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
A randomized double blind multicenter trial comparing the pharmacodynamic and clinical activities of 5682 SE (a micronized flavonoid fraction containing diosmin and hesperidin) to non-micronized diosmin in 90 patients with chronic venous insufficiency. The study found more substantial improvements in clinical symptoms and venous outflow parameters with 5682 SE.
[Results of the use of topical diosmin (venosmine) in the treatment of acute hemorrhoid pathology].
RCT of topical diosmin ointment on 50 patients with grade 1-4 haemorrhoids featuring strangulation and thrombosis. Diosmin was most effective on oedema and erythema, producing 75% and 73% improvements, respectively, with no unwanted side effects.
Isolation and bioactive evaluation of flavonoid glycosides from Lobelia chinensis Lour using two-dimensional liquid chromatography combined with label-free cell phenotypic assays.
The study developed a method for isolating flavonoid glycosides from Lobelia chinensis using a 2D-HILIC × RPLC system. Nine compounds were isolated, including seven novel flavonoid glycosides, lobelitin A-G. Four of these showed agonistic activities at G protein-coupled receptor 35 (GPR35) in cell phenotypic assays.
Sulodexide and phlebotonics in the treatment of venous ulcer.
Observational study comparing the effects of diosmin-hesperidin (DH) alone versus combined with sulodexide (SDX) in the treatment of venous ulcers. The group receiving SDX showed faster ulcer size reduction and healing by week 12 compared to the control group, which healed by week 21. Lipodermatosclerosis improved faster in the SDX group.
The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients.
Double blind placebo-controlled study of Daflon 500 (flavonoids diosmin and hesperidin) in 28 Type 1 diabetic patients. Treatment decreased HbA1c and increased glutathione peroxidase activity, suggesting flavonoid-induced decrease in glycation is associated with increased antioxidant activity.
[Study of the pharmacodynamic activity of daflon 500 mg].
Double-blind placebo-controlled trial of Daflon 500 mg, a micronized purified flavonoid fraction composed of 90% diosmin and 10% hesperidin, in 10 women without venous disease. The study demonstrated that venous tone was significantly reinforced by the 1st hour after a single dose, with effects persisting for 4 to 24 hours.
Diosmin pretreatment affects bioavailability of metronidazole.
Non-blinded investigation in 12 healthy male volunteers assessing the effect of diosmin pretreatment on the metabolism of metronidazole. Diosmin pretreatment significantly increased metronidazole plasma AUC and C(max) by 27% and 24%, respectively, and altered urinary excretion patterns, suggesting inhibition of cytochrome P(450) enzymes.
Micronized flavonoid therapy in internal hemorrhoids of pregnancy.
Open study on 50 pregnant women with acute hemorrhoids treated with micronized diosmin 90% and hesperidin 10% for a median of 8 weeks before delivery and 4 weeks after. 66% had relief from acute symptoms by the 4th day, and 53.6% fewer patients had relapse in the antenatal period. Treatment was well accepted and did not affect pregnancy or fetal development.
An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency.
Open pilot study on 24 patients with third-stage chronic venous insufficiency treated with Daflon 500 mg, a micronized purified flavonoid fraction containing diosmin and hesperidin. The study evaluated changes in capillary packed cell volume and red blood cell velocity before and after treatment, showing significant increases in both parameters, suggesting improved red blood cell flexibility and haemorheological effects.